Stay updated with breaking news from Lexaria Bioscience. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
DehydraTECH Pharmaceutical License Issued for the European, Australian and New Zealand marketsLexaria to receive royalty revenue from DehydraTECH product salesKELOWNA, BC / ACCESSWIRE / June 8, 2022 /
Minimum payments due to Lexaria of US$4,527,500 over the first five years to retain exclusivityLexaria to receive royalty revenue from DehydraTECH product salesKELOWNA, BC / ACCESSWIRE / June 2, 2022 /
June 3, 2022 Company name Premier Anti-Aging Co., Ltd. Representative Representative Kiyoshi Matsuura, President and... | June 3, 2022
Contract Manufacturing Organization first in Europe to License DehydraTECHLexaria will receive milestone fees and royalty payments from product salesKELOWNA, BC / ACCESSWIRE / June 2, 2022 / Lexaria Bioscience
KELOWNA, BC / ACCESSWIRE / June 1, 2022 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces the results of the 2022